Document is current
Any future updates will be listed below
-
Authors
Watamura, Naoto https://orcid.org/0000-0001-7971-7378
Foiani, Martha S. https://orcid.org/0000-0003-4157-2606
Bez, Sumi https://orcid.org/0000-0002-8971-5103
Bourdenx, Mathieu
Santambrogio, Alessia
Frodsham, Claire
Camporesi, Elena
Brinkmalm, Gunnar https://orcid.org/0000-0001-6958-2393
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Patel, Saisha
Kamano, Naoko
Takahashi, Mika
Rueda-Carrasco, Javier
Katsouri, Loukia https://orcid.org/0000-0003-0186-6116
Fowler, Stephanie https://orcid.org/0000-0001-6693-9959
Turkes, Emir
Hashimoto, Shoko
Sasaguri, Hiroki https://orcid.org/0000-0003-2550-9156
Saito, Takashi https://orcid.org/0000-0002-9659-9251
Islam, AFM Saiful
Benner, Seico
Endo, Toshihiro
Kobayashi, Katsuji
Ishida, Chiho https://orcid.org/0000-0002-1948-5381
Vendruscolo, Michele https://orcid.org/0000-0002-3616-1610
Yamada, Masahito
Duff, Karen E. https://orcid.org/0000-0002-6177-868X
Saido, Takaomi C. https://orcid.org/0000-0003-1970-6903
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20dm0207001)
MEXT | Japan Society for the Promotion of Science (21K15378)
U.S. Department of Health & Human Services | National Institutes of Health (AG063521)
- License Information
-
More Information
Article History
Received: 28 May 2023
Accepted: 23 October 2024
First Online: 24 December 2024
Competing interests
: T.E. serves as a Representative for Phenovance LLC, which provides commercial service using IntelliCage. T.C.S. serves as an Executive Consultant for RIKEN BIO Co. Ltd., which sublicenses App knock-in mice to for-profit organizations. K.E.D. is a board member of Ceracuity LLC. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare no competing interests.
